Antibody Cocktails at Low Doses Could Be More Effective at Treating COVID-19, Finds Study
By HospiMedica International staff writers Posted on 24 Nov 2020 |
Image: Timothy P. Sheahan (Photo courtesy of University of North Carolina at Chapel Hill)
Pairs of antibodies may be more effective than single antibodies at preventing and treating COVID-19, according to a new study.
Researchers at the University of North Carolina at Chapel Hill (Chapel Hill, NC, USA) and The Rockefeller University (New York, NY, USA) who conducted the study have also suggested that in addition to blocking SARS-CoV-2's entry into cells, the antibodies may combat the virus by enlisting various types of white blood cells to fight the infection.
Human antibodies that neutralize SARS-CoV-2 hold great potential for preventing and treating COVID-19, and researchers have identified several potent antibodies that bind to the spike protein on the virus's surface, thereby preventing it from mediating the virus's entry into cells. The researchers tested the ability of several human antibodies to prevent SARS-CoV-2 infection in mice or hamsters. Surprisingly, they found that certain antibodies were more potent than expected. Some antibodies that were relatively poor at blocking viral entry into cultured cells were much more effective at preventing SARS-CoV-2 infection in rodents. The researchers determined that this was partly because, in addition to blocking viral entry, the antibodies can activate various types of white blood cells. These "antibody effector functions" help the immune system target the virus and/or virally infected cells.
The researchers also found that antibodies may be even more effective when used in combination with each other. Pairs of antibodies that target slightly different parts of the viral spike protein could successfully prevent or treat SARS-CoV-2 infection in mice and hamsters at much lower doses than single-antibody treatments. This is a particularly attractive approach because targeting multiple parts of the spike protein reduces the chance of the virus mutating and becoming resistant to antibody treatments.
"Some antibody combinations can be effective for prevention and early therapy of SARS-CoV-2 even at relatively low doses," said Timothy P. Sheahan, an assistant professor at the Gillings School of Public Health at the University of North Carolina at Chapel Hill. "Overall, our data support the idea that specific combinations of antibodies with the ability to activate immune cells should be developed for optimal protection and therapy against SARS-CoV-2."
Related Links:
University of North Carolina at Chapel Hill
The Rockefeller University
Researchers at the University of North Carolina at Chapel Hill (Chapel Hill, NC, USA) and The Rockefeller University (New York, NY, USA) who conducted the study have also suggested that in addition to blocking SARS-CoV-2's entry into cells, the antibodies may combat the virus by enlisting various types of white blood cells to fight the infection.
Human antibodies that neutralize SARS-CoV-2 hold great potential for preventing and treating COVID-19, and researchers have identified several potent antibodies that bind to the spike protein on the virus's surface, thereby preventing it from mediating the virus's entry into cells. The researchers tested the ability of several human antibodies to prevent SARS-CoV-2 infection in mice or hamsters. Surprisingly, they found that certain antibodies were more potent than expected. Some antibodies that were relatively poor at blocking viral entry into cultured cells were much more effective at preventing SARS-CoV-2 infection in rodents. The researchers determined that this was partly because, in addition to blocking viral entry, the antibodies can activate various types of white blood cells. These "antibody effector functions" help the immune system target the virus and/or virally infected cells.
The researchers also found that antibodies may be even more effective when used in combination with each other. Pairs of antibodies that target slightly different parts of the viral spike protein could successfully prevent or treat SARS-CoV-2 infection in mice and hamsters at much lower doses than single-antibody treatments. This is a particularly attractive approach because targeting multiple parts of the spike protein reduces the chance of the virus mutating and becoming resistant to antibody treatments.
"Some antibody combinations can be effective for prevention and early therapy of SARS-CoV-2 even at relatively low doses," said Timothy P. Sheahan, an assistant professor at the Gillings School of Public Health at the University of North Carolina at Chapel Hill. "Overall, our data support the idea that specific combinations of antibodies with the ability to activate immune cells should be developed for optimal protection and therapy against SARS-CoV-2."
Related Links:
University of North Carolina at Chapel Hill
The Rockefeller University
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans